KIF11 and osteosarcoma: We also tested other cancer cell lines, such as osteosarcoma and rhabdomyosarcoma, and observed synergy with this drug combination in our preliminary studies (Supplementary Figure S6), which is consistent with elevated KIF11 and KIF15 levels (Figure 1A), indicating the potential for this drug combination in targeting other tumor types, especially sarcomas.